News and Events from NHTherapeutics

January 19th, 2017

NHTherapeutics is granted Orphan Drug Designation by the European Medicines Agency

December 8th, 2015

John Kaiser joins NHTherapeutics Board of Directors

September 8th, 2015

NHTherapeutics has begun research and development of buccal leuprolide and made the first tranche of payments to Generex, its formulation partner.

May 26th, 2015

NHTherapeutics has entered into a Memorandum of Understanding with Generex pursuant to which the companies will co-develop a formulation for the delivery of Leuprolide into the human body via the buccal mucosa using the Generex proprietary RapidMist™ buccal drug delivery system.